skip to main content
UK Health Security Agency

FLO-1

FLO-1

Catalogue No.

11012001

Cell Line Name

FLO-1

Cell Line Description

FLO-1 was established from a primary distal oesophageal adenocarcinoma in a 68 year-old Caucasian male in 1991. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis. Cultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer

Characteristics

Receptors

Not specified

Products

P53 mutation c.830G>T

Tissue of Origin

Oesophagus

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11
D5S818: 12,14
D7S820: 8
D13S317: 11
D16S539: 12,13
TH01: 6
TPOX: 9,11
vWA: 16

Karyotype

Not specified

Disease

Adenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:4 to 1:8 i.e. seeding at 1-3 x 10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Saturation density approx 10⁵ cells/cm².

Culture Medium

DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)

Growth Mode

Adherent

Additional Info

Depositor

Dr W.N.M. Dinjens, Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Centre, Rotterdam PO Box 2040, 3000CA Rotterdam. Originator: Dr D.G. Beer University of Michigan, Ann Arbor MI 48109-5942.

Country of Origin

United States

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG 1997 Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 57(24):5571-8. PMID: 9407969Whole-genome sequencing of nine esophageal adenocarcinoma cell lines

Bibliography

Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. 2010 Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 102(4):271-4.PMID: 20075370.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: FLO-1 (ECACC 11012001).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.